[18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers.
Emma E WoltersJanne M PapmaSander C J VerfaillieDenise VisserEmma WeltingsColin GrootEmma Louise van der EndeLucia A A GianniniHayel TuncelTessa TimmersRonald BoellaardMaqsood M YaqubDanielle M E van AssemaDennis A KuijperMarcel SegbersAnnemieke J M RozemullerFrederik BarkhofAlbert D WindhorstWiesje Maria van der FlierYolande A L PijnenburgPhilip ScheltensBart N M van BerckelJohn Cornelis van SwietenRik OssenkoppeleHarro SeelaarPublished in: Neurology (2021)
Presymptomatic MAPT mutation carriers already showed subtle elevated tau binding, whereas symptomatic MAPT mutation carriers showed a more marked increase in [18F]flortaucipir BPND. Tau deposition was most pronounced in R406W MAPT (pre)symptomatic mutation carriers, which is associated with both 3R and 4R tau accumulation. Thus, [18F]flortaucipir may serve as an early biomarker for MAPT mutation carriers in mutations that cause 3R/4R tauopathies.
Keyphrases